Clinical trials: Prostate Cancer Metastatic to Bone
Prostate Cancer, Bone-only Metastatic Castration-Resistant Prostate Cancer (CRPC)
A Study of Radium-223 in Combination With Tasquinimod in Bone-only Metastatic Castration-Resistant Prostate Cancer
This is a Phase I/Ib study of Radium-223 in combination with Tasquinimod for patients with bone metastases from castration-resistant prostate cancer (CRPC).
- Trial name
- Radium-223 (NCT02396368)
- Testing
- Tasquinimod, Radium 223
- Where
- United States
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Leukemia, Lymphoma
Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of suberoylanilide hydroxamic acid in treating patients who…
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Prostate Cancer
- Trial name
- NCT00005634
- Testing
- vorinostat
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Metastatic Cancer, Pain
Tandutinib in Treating Patients With Progressive Prostate Cancer and Bone Metastases
RATIONALE: Tandutinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well tandutinib works in treating patients with progressive prostate…
- Conditions
- Metastatic Cancer, Pain, Prostate Cancer
- Trial name
- NCT00390468
- Testing
- Tandutinib
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- National Cancer Institute (NCI)
Cancer
Laboratory Assay in Determining Cancer Resistance in Patients With Metastatic Cancer and in Healthy Participants
RATIONALE: Studying samples of blood and tissue in the laboratory from patients with cancer and from healthy participants may help doctors learn more about cancer.
- Trial name
- NCT00899496
- Testing
- immunological diagnostic method, physiologic testing
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Prostate Cancer
Open Label Phase Two Trial of Radium Ra 223 Dichloride With Concurrent Administration of Abiraterone Acetate Plus Prednisone in Symptomatic Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Bone Metastasis
This is an open label study designed to examine the effects on concurrent administration of Radium Ra 223 dichloride and Abiraterone Acetate plus Prednisone in subjects with symptomatic castrate resistant prostate cancer and with…
- Trial name
- eRADicAte (NCT02097303)
- Testing
- Concurrent use of Radium Ra 223 dichloride and Abiraterone Acetate plus Prednisone
- Where
- 5 sites in United States
- Volunteers
- 36 people
- Sponsor
- Carolina Research Professionals, LLC
Breast Cancer, Lung Cancer
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
RATIONALE: Gathering information about how often osteonecrosis of the jaw occurs in patients receiving zoledronic acid for bone metastases may help doctors learn more about the disease and provide the best follow-up care.
- Conditions
- Breast Cancer, Lung Cancer, Metastatic Cancer, Multiple Myeloma
- Trial name
- NCT00874211
- Testing
- assessment of therapy complications
- Where
- 453 sites in United States, Mexico and 1 more
- Volunteers
- 3,571 people
- Sponsor
- SWOG Cancer Research Network
Prostate Cancer
ZOMETA® (Zoledronic Acid) for Prevention of Bone Metastases
To determine if therapy with Zometa® (zoledronic acid) 4mg will be effective in preventing the occurrence of bone metastases in prostate cancer patients at high risk of developing them.
- Trial name
- NCT00294437
- Testing
- Zometa
- Where
- 57 sites in Austria, Bosnia and Herzegovina and 14 more
- Volunteers
- 376 people
- Sponsor
- Central European Cooperative Oncology Group
Prostate Cancer
Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
It is the aim of this prospective, single-group, clinical study to assess whether bone parameters can be used as diagnostic tools for early detection of bone metastases in patients with high risk prostate cancer.
- Trial name
- NCT00391690
- Testing
- Zoledronic acid
- Where
- Germany
- Volunteers
- 99 people
- Sponsor
- Novartis
Breast Cancer, Lung Cancer
Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer
RATIONALE: Zoledronate, vitamin D and calcium may prevent or delay bone pain and other symptoms caused by bone metastases. It is not yet known whether giving zoledronate together with vitamin D and calcium is more effective with…
- Conditions
- Breast Cancer, Lung Cancer, Metastatic Cancer, Pain
- Trial name
- NCT00365105
- Testing
- Calcium, Vitamin D, zoledronic acid
- Where
- 147 sites in United States
- Volunteers
- 261 people
- Sponsor
- Radiation Therapy Oncology Group
Bone Cancer, Bone Metastases
Study Comparing the Safety and Effectiveness of Magnetic Resonance Guided Focused Ultrasound (MRgFUS) and External Beam Radiation (EBRT) for Treatment of Metastatic Bone Tumors and Multiple Myeloma
The goal of this study is to collect comparative data on safety and efficacy of MR Guided Focused Ultrasound and External Beam Radiation for treatment of metastatic bone tumors or multiple myeloma.
- Conditions
- Bone Cancer, Bone Metastases, Pain
- Trial name
- NCT01091883
- Testing
- Exablate treatment, Radiation
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- InSightec
Prostate Cancer
Phase I Clinical Trial of Cryoimmunotherapy Against Prostate Cancer
20 patients with invasive castration resistant prostate cancer and radiologically verified metastases will be enrolled into the Phase I Clinical Trial. The trial is a dendritic cell based immunotherapy.
- Trial name
- CryoIT (NCT02423928)
- Testing
- Dendritic cell based cryoimmunotherapy, Cyclophosphamide, ipilimumab
- Where
- Norway
- Volunteers
- 18 people
- Sponsor
- Alden Cancer Therapy II
Hormone Refractory Prostate Cancer, Bone Metastases
A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases
ALSYMPCA (ALpharadin in SYMPtomatic Prostate CAncer) is an international Phase III clinical study to evaluate the efficacy and safety of Radium-223 dichloride in patients with hormone refractory prostate cancer and skeletal…
- Trial name
- ALSYMPCA (NCT00699751)
- Testing
- Radium-223 dichloride (Xofigo, BAY88-8223), Best standard of care (BSoC)
- Where
- 134 sites in United States, Australia and 17 more
- Volunteers
- 921 people
- Sponsor
- Bayer
Malignant Digestive System Neoplasm, Metastatic Head and Neck Carcinoma
Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Compressing the Spinal Cord
This phase II clinical trial studies how well thermal ablation and spine stereotactic radiosurgery work in treating patients with cancer that has spread to the spine (spine metastases) and is at risk for compressing the spinal…
- Conditions
- Malignant Digestive System Neoplasm, Metastatic Head and Neck Carcinoma, Metastatic Kidney Carcinoma, Metastatic Malignant Neoplasm in the Spine
- Trial name
- NCT02713269
- Testing
- Computed Tomography, Quality-of-Life Assessment, Questionnaire Administration
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Cancer, Prostate Cancer
S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy
RATIONALE: Drugs used in chemotherapy, such as docetaxel, prednisone, and atrasentan work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00134056
- Testing
- atrasentan hydrochloride, docetaxel, prednisone
- Where
- 554 sites in United States
- Volunteers
- 1,038 people
- Sponsor
- SWOG Cancer Research Network
Bladder Small Cell Neuroendocrine Carcinoma, Castration-Resistant Prostate Carcinoma
Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate
This phase Ib trial studies how well pembrolizumab works with combination chemotherapy in treating participants with small cell/neuroendocrine cancers of the urothelium or prostate that has spread to nearby tissue or lymph nodes…
- Conditions
- Bladder Small Cell Neuroendocrine Carcinoma, Castration-Resistant Prostate Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma
- Trial name
- NCT03582475
- Testing
- Carboplatin, Cisplatin, Docetaxel
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Prostate Cancer, Bone Metastases
A Phase I/II Open-label Study of MCS110 in Patients With Prostate Cancer and Bone Metastases
This study will evaluate the safety and efficacy of MCS110 in patients with prostate cancer and bone metastases
- Trial name
- NCT00757757
- Testing
- MCS110
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- Novartis Pharmaceuticals
Prostatic Neoplasms
Radium-223 Dichloride (BAY88-8223) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases
This study is a prospective, interventional, open-label, multi-center early access program for the use of Ra-223 Cl2 in HRPC/CRPC patients diagnosed with symptomatic bone metastasis and to collect additional short and long term…
- Trial name
- NCT01516762
- Testing
- Radium-223 dichloride (BAY88-8223)
- Where
- 60 sites in United States
- Sponsor
- Bayer
Prostate Carcinoma Metastatic to the Bone
Open Label Phase Two Study of Enzalutamide With Concurrent Administration of Radium Ra 223 Dichloride in Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Symptomatic Bone Metastasis
This is an open label study designed to examine the effects of Enzalutamide with concurrent administration of Radium Ra 223 dichloride in Castrate-Resistant (Hormone-Refractory) Prostate Cancer subjects with symptomatic bone…
- Trial name
- NCT02507570
- Testing
- Enzalutamide, Radium ra 223 dichloride
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- Carolina Research Professionals, LLC
Prostate Cancer With ≤10 Bone Metastases
Efficacy and Safety of Apalutamide in Combination With 89Sr as Neoadjuvant Therapy in Prostate Cancer With ≤10 Bone Metastases
The aim of this study is to evaluate the efficacy and safety of apalutamide in combination with 89Sr as neoadjuvant therapy in prostate cancer with ≤10 bone metastases.
- Trial name
- NCT05740488
- Testing
- Apalutamide, 89Sr, Luteinizing Hormone-Releasing Hormone Analog
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Zhujiang Hospital
Prostate Cancer Metastatic, Castration Resistant Prostatic Cancer
Prospective REgistry of Targeted RadionucLide TherapY in Patients With mCRPC (REALITY Study)
This prospective registry aims to assess outcome and toxicity of targeted radionuclide therapies in patients with advanced prostate cancer in clinical routine.
- Conditions
- Prostate Cancer Metastatic, Castration Resistant Prostatic Cancer, Advanced Prostate Carcinoma
- Trial name
- NCT04833517
- Where
- Germany
- Volunteers
- 500 people
- Sponsor
- Universität des Saarlandes